Ionis Pharmaceuticals Earns Relative Strength Rating Upgrade

Ionis Pharmaceuticals (IONS) saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, rising from 88 to 92.


When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. IBD’s proprietary RS Rating measures market leadership by showing how a stock’s price movement over the last 52 weeks compares to that of the other stocks in our database.

Decades of market research reveals that the stocks that go on to make the biggest gains often have an RS Rating of over 80 at the beginning of a new run.

See How IBD Helps You Make More Money In Stocks

Ionis Pharmaceuticals is working on a consolidation with a 48.92 buy point. See if it can clear the breakout price in volume at least 40% higher than normal.

The company posted 0% EPS growth last quarter, while sales growth came in at 20%.

Ionis Pharmaceuticals earns the No. 76 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals (CPRX), Genmab ADR (GMAB) and Harmony Biosciences (HRMY) are among the top 5 highly rated stocks within the group.


Biotech And Pharmaceutical Industry And Stock News

IBD Stock Rating Upgrades: Rising Relative Strength

Why Should You Use IBD’s Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

Evaluate Any Stock With Stock Ratings, IBD Charts And Stock Checkup

Most Related Links :
Public News Time Latest News Sports News Finance News Automobile News

Root link

Related Articles

Back to top button